Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of [14C] Vebicorvir in Healthy Men
NCT04637139Phase 1Completed
- Sponsor
- Assembly Biosciences, Inc.
- Start
- Dec 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vebicorvir in Chronic Hepatitis B (CHB), sponsored by Assembly Biosciences, Inc. Primary endpoints: Cumulative Amount of [14C] Radiolabel Excreted in Urine at 168 hours and Cumulative Amount of [14C] Radiolabel Excreted in Feces at 168 hours. Started Dec 2020; status: completed.
02
Drugs
vebicorvir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04637139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04637139.